COLGATE-PALMOLIVE (CL)
Sector: Consumer Staples
2026 Annual Meeting Analysis
COLGATE-PALMOLIVE · Meeting: May 8, 2026
Directors FOR
10
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
11-year tenure, no overboarding concerns (one current public board seat), attendance satisfactory, and CL's 3-year TSR of +26.8% outperforms the peer group median by +33.7pp — well below the 65pp threshold required to trigger a vote against.
Joined the board in March 2026 — less than 24 months ago — so is fully exempt from the TSR underperformance trigger; serves as CEO of Bristol-Myers Squibb which is his only outside board seat, satisfying the sitting-CEO limit of fewer than two outside public board seats.
21-year tenured director with strong finance and consumer-goods credentials; holds three other public board seats (American Airlines, Autodesk, Kraft Heinz) which is within the policy limit of fewer than four; the board confirmed this does not impair his service; TSR trigger does not apply given CL's strong outperformance of the peer median.
7-year tenure with relevant digital, cybersecurity, and governance expertise; no other public board seats; TSR trigger does not apply; no other policy flags identified.
10-year tenure with relevant technology, healthcare, and cybersecurity expertise; holds two other public board seats (Claritev, Thermo Fisher) which is within policy limits; TSR trigger does not apply; no other policy flags identified.
6-year tenure with deep CFO-level finance expertise at Mastercard; holds two other public board seats (GE Vernova, Prudential) within policy limits; TSR trigger does not apply; no other policy flags identified.
5-year tenure with strong consumer-goods and sustainability background from General Mills; holds two other public board seats (Cummins, Tate & Lyle) within policy limits; TSR trigger does not apply; no other policy flags identified.
Joined the board in 2024 — approximately two years ago — placing him near the 24-month new-director exemption boundary; given tenure covers less than half the 3-year measurement period the policy calls for flagging but not automatically voting against; no other policy flags; strong CFO credentials at CVS Health and UPS are highly relevant.
11-year tenure as Lead Director with extensive technology and governance experience; holds two current public board seats (Asana, HubSpot) within policy limits after stepping down from Autodesk in mid-2025; TSR trigger does not apply; no other policy flags identified.
CEO-director subject to the same TSR trigger as all other directors; CL's 3-year TSR of +26.8% outperforms the peer group median by +33.7pp, well below the 65pp threshold needed to trigger an against vote; one outside board seat (American Express, joined July 2025) is within the limit of fewer than two outside seats for a sitting CEO.
All ten director nominees pass the policy screens. CL's 3-year total shareholder return of +26.8% outperforms the company-disclosed peer group median by +33.7 percentage points, comfortably below the 65pp threshold (applicable because absolute 3-year TSR exceeds +20%) that would trigger votes against incumbent directors. No director is overboarded under the policy's limits. Board attendance averaged 96% in 2025 with no director below the 75% threshold. All audit and compensation committee members are independent. No familial relationships with senior management were identified.
Say on Pay
✓ FORCEO
Noel Wallace
Total Comp
$16,478,196
Prior Support
N/A
CEO Noel Wallace received total compensation of approximately $16.5 million in 2025, which is consistent with expectations for the CEO of a large-cap ($68.5B market cap) Consumer Defensive company and is positioned between the median and 75th percentile of the company's peer group — within acceptable benchmarking range. The pay structure is strongly performance-oriented: approximately 90% of CEO target pay is variable, well above the 50-60% policy threshold, with long-term incentives comprising performance-based stock awards tied to three-year relative organic sales growth, relative net income growth, free cash flow productivity, and a total shareholder return modifier — all meaningful, multi-year metrics. The pay-for-performance alignment check is satisfied: CL's 3-year total shareholder return of +26.8% outperforms the peer median by +33.7pp, so above-median variable pay is justified by shareholder outcomes. The company maintains robust clawback policies covering both mandatory restatement recoupment (NYSE-compliant) and a broader discretionary policy tied to code-of-conduct violations.
Auditor Ratification
✓ FORAuditor
PricewaterhouseCoopers LLP
Tenure
N/A
Audit Fees
N/A
Non-Audit Fees
N/A
PwC is a Big 4 firm fully appropriate for a company of Colgate-Palmolive's size and global complexity. Auditor fee data was not extractable from the truncated proxy text provided, so the non-audit fee ratio trigger cannot be calculated — per policy, when fee data is unavailable the default FOR vote applies and the absence of fee data is noted as a minor informational gap. No disclosed material financial restatements were identified. Auditor tenure was not disclosed in the available filing text; per policy, when tenure cannot be confirmed the tenure trigger does not fire and the default FOR vote applies.
Stockholder Proposals
2 proposals submitted by shareholders
Proposal 4
Remove DEI from Board Candidate Considerations
This proposal asks the company to stop considering diversity as a factor in selecting board candidates. Based on the proposal title and the board's opposition, this fits the pattern of ideologically motivated conservative proposals that use governance framing to advance political goals rather than genuine shareholder interests. Under the voting policy's symmetry rule, proposals driven by ideological motivation from either direction — conservative or progressive — are voted against, because the test is whether a neutral fiduciary investor would submit this proposal; this one only makes sense as political advocacy. The board already discloses a skills-based matrix and independence standards that form the core of its director selection process, and the proposal would restrict the board's legitimate ability to compose a well-rounded board that reflects the global markets in which Colgate-Palmolive competes.
Proposal 5
Independent Board Chairman
Separating the CEO and Board Chairman roles is a mainstream governance improvement that removes a structural conflict of interest — the same person currently sets the board's agenda and runs day-to-day management, which can limit independent oversight even with a strong Lead Director in place. While Colgate-Palmolive has a robust Lead Director role with meaningful authority, the Lead Director is appointed by the board itself rather than directly elected by shareholders, and the combined Chairman-CEO role means the CEO can still influence what matters come before the board. Requiring an independent chairman is a widely supported governance reform that gives shareholders greater assurance of independent board oversight, particularly important at a company where the CEO has also served as Chairman since 2020.
Overall Assessment
Colgate-Palmolive's 2026 annual meeting ballot is broadly supportable: all ten director nominees pass the overboarding, attendance, independence, and TSR performance screens, and the executive compensation program reflects a genuinely performance-oriented structure with strong stock outperformance versus peers over three years. The two stockholder proposals receive split treatment — the independent chairman proposal is supported as a mainstream governance improvement, while the proposal to remove diversity considerations from board candidate selection is voted against as an ideologically motivated conservative proposal that does not serve neutral shareholder interests.
Compensation Peer Group
14 companies disclosed in 2026 proxy filing